Assessing efficacy of combined riboflavin and UV-A light (365 nm) treatment of acanthamoeba trophozoites

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 13, 2011, Pages 9333-9338

  Kashiwabuchi, Renata T ^a   Carvalho, Fabio R S ^a   Khan, Yasin A ^b   de Freitas, Denise ^a   Foronda, Annette S ^a,c   Hirai, Flavio E ^a   Campos, Mauro S ^a   McDonnell, Peter J ^b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

PROPAMIDINE ISETHIONATE; RIBOFLAVIN; VITAMIN B COMPLEX;

ACANTHAMOEBA KERATITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL VIABILITY; CHINESE HAMSTER; CONTROLLED STUDY; CORNEA STROMA; DISEASE COURSE; DRUG EFFICACY; FEMALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; ULTRAVIOLET A RADIATION; ANIMAL; CORNEA; DISEASE MODEL; DRUG EFFECT; FOLLOW UP; HAMSTER; HUMAN; METHODOLOGY; MIDDLE AGED; PARASITOLOGY; PATHOLOGY; PHOTOTHERAPY; RADIATION EXPOSURE; TREATMENT OUTCOME;

ACANTHAMOEBA KERATITIS; ANIMALS; CORNEA; CRICETINAE; DISEASE MODELS, ANIMAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; RIBOFLAVIN; TREATMENT OUTCOME; ULTRAVIOLET THERAPY; VITAMIN B COMPLEX;

EID: 84856316265     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.11-8382     Document Type: Article

References (37)

1. Visvesvara GS, Moura H, Schuster FL. Pathogenic and opportunistic free-living amoebae: Acanthamoeba spp., Balamuthia mandrillaris, Naegleria fowleri, and Sappinia diploidea. FEMS Immunol Med Microbiol. 2007;50:1-26.
2. Carvalho FR, Foronda AS, Mannis MJ, et al. Twenty years of Acanthamoeba keratitis. Cornea. 2009;28:516-519.
3. Dart JK, Saw VP, Kilvington S. Acanthamoeba keratitis: diagnosis and treatment update 2009. Am J Ophthalmol. 2009;148:487-499.
4. Lim N, Goh D, Bunce C, et al. Comparison of polyhexamethylene biguanide and chlorhexidine as monotherapy agents in the treatment of Acanthamoeba keratitis. Am J Ophthalmol. 2008;145: 130-135.
5. Gooi P, Lee-Wing M, Brownstein S, et al. Acanthamoeba keratitis: persistent organisms without inflammation after 1 year of topical chlorhexidine. Cornea. 2008;27:246-248.
6. Iovieno A, Oechsler RA, Ledee DR, et al. Drug-resistant severe Acanthamoeba keratitis caused by rare T5 Acanthamoeba genotype. Eye Contact Lens. 2010;36:183-184.
7. McClellan K, Howard K, Niederkorn JY, Alizadeh H. Effect of steroids on Acanthamoeba cysts and trophozoites. Invest Ophthalmol Vis Sci. 2001;42:2885-2893.
8. Herz NL, Matoba AY, Wilhelmus KR. Rapidly progressive cataract and iris atrophy during treatment of Acanthamoeba keratitis. Ophthalmology. 2008;115:866-869.
9. Kashiwabuchi RT, de Freitas D, Alvarenga LS, et al. Corneal graft survival after therapeutic keratoplasty for Acanthamoeba keratitis. Acta Ophthalmol. 2008;86:666-669.
10. Kitzmann AS, Goins KM, Sutphin JE, Wagoner MD. Keratoplasty for treatment of Acanthamoeba keratitis. Ophthalmology. 2009; 116:864-869.
11. Ficker LA, Kirkness C, Wright P. Prognosis for keratoplasty in Acanthamoeba keratitis. Ophthalmology. 1993;100:105-110.
12. Pérez-Santonja JJ, Kilvington S, Hughes R, et al. Persistently culture positive Acanthamoeba keratitis: in vivo resistance and in vitro sensitivity. Ophthalmology. 2003;110:1593-1600.
13. Qian Y, Meisler DM, Langston RH, Jeng BH. Clinical experience with Acanthamoeba keratitis at the Cole Eye Institute. 1999-2008. Cornea. 2010;29:1016-1021.
14. Morén H, Malmsjö M, Mortensen J, Ohrström A. Riboflavin and ultraviolet a collagen crosslinking of the cornea for the treatment of keratitis. Cornea. 2010;29:102-104.
15. Khan YA, Kashiwabuchi RT, Martins SA, et al. Riboflavin and ultraviolet light a therapy as an adjuvant treatment for medically refractive Acanthamoeba keratitis: report of 3 cases. Ophthalmology. 2011;118:324-331.
16. Wollensak G, Spoerl E, Seiler T. Riboflavin/ultraviolet-A-induced collagen crosslinking for the treatment of keratoconus. Am J Ophthalmol. 2003;135:620-627.
17. Pelletier JP, Transue S, Snyder EL. Pathogen inactivation techniques. Best Pract Res Clin Haematol. 2006;19:205-242.
18. Van Voorhis WC, Barrett LK, Eastman RT, et al. Trypanosoma cruzi inactivation in human platelet concentrates and plasma by a psoralen (amotosalen HCl) and long-wavelength UV. Antimicrob Agents Chemother. 2003;47:475-479.
19. Carvalho FRS, Foronda AS, Pellizari VH. Detection of Legionella pneumophila in water and biofilm samples by culture and molecular methods from man-made systems in Sao Paulo-Brazil. Braz J Microbiol. 2007;38:743-751.
20. Neff RJ. Purification, axenic cultivation, and description of a soil amoeba. J Protozool. 1957;4:176-182.
21. Schroeder JM, Booton GC, Hay J, et al. Use of subgenic 18S ribosomal DNA PCR and sequencing for genus and genotype identification of Acanthamoebae from humans with keratitis and from sewage sludge. J Clin Microbiol. 2001;39:1903-1911.
22. Altschul SF, Madden TL, Schäffer AA, et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 1997;25:3389-3402.
23. van Klink F, Alizadeh H, He Y, et al. The role of contact lenses, trauma, and Langerhans cells in a Chinese hamster model of Acanthamoeba keratitis. Invest Ophthalmol Vis Sci. 1993;34: 1937-1944.
24. Iseli HP, Hafezi F, Kampmeier J, et al. Ultraviolet A/riboflavin corneal cross-linking for infectious keratitis associated with corneal melts. Cornea. 2008;27:590-594.
25. Micelli Ferrari T, Leozappa M, Lorusso M, et al. Escherichia coli keratitis treated with ultraviolet A/riboflavin corneal cross-linking: a case report. Eur J Ophthalmol. 2009;19:295-297.
26. Makdoumi K, Mortensen J, Crafoord S. Infectious keratitis treated with corneal crosslinking. Cornea. 2010;29:1353-1358.
27. Panjwani N. Pathogenesis of Acanthamoeba keratitis. Ocul Surf. 2010;8:70-79.
28. Ehlers N, Hjortdal J. Are cataract and iris atrophy toxic complications of medical treatment of Acanthamoeba keratitis? Acta Ophthalmol Scand. 2004;82:228-231.
29. Rama P, Di Matteo F, Matuska S, et al. Acanthamoeba keratitis with perforation after corneal crosslinking and bandage contact lens use. J Cataract Refract Surg. 2009;35:788-791.
30. Ruane PH, Edrich R, Gampp D, et al. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion. 2004;44:877-885.
31. Joshi P. Comparison of the DNA-damaging property of photosensitised riboflavin via singlet oxygen (1O2) and superoxide radical O2-. mechanisms. Toxicol Lett. 1985;26:211-217.
32. Kumar V, Lockerbie O, Keil SD, et al. Riboflavin and UV-light based pathogen reduction: extent and consequence of DNA damage at the molecular level. Photochem Photobiol. 2004;80:15-21.
33. Spoerl E, Wollensak G, Seiler T. Increased resistance of crosslinked cornea against enzymatic digestion. Curr Eye Res. 2004;29:35-40.
34. de Souza Carvalho FR, Carrijo-Carvalho LC, Chudzinski-Tavassi AM, et al. Serine-like proteolytic enzymes correlated with differential pathogenicity in patients with acute Acanthamoeba keratitis. Clin Microbiol Infect. 2011;17:603-609.
35. Wollensak G, Iomdina E. Biomechanical and histological changes after corneal crosslinking with and without epithelial debridement. J Cataract Refract Surg. 2009;35:540-546.
36. Goodrich RP, Edrich RA, Li J. The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends. Transfus Apher Sci. 2006;35:5-17.
37. Spoerl E, Mrochen M, Sliney D, et al. Seiler Safety of UV-A-riboflavin cross-linking of the cornea. Cornea. 2007;26:385-389.